Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Acrigen Biosciences

Main focus: Next-generation safe gene-editing therapies

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-Cas

Funding stage: Private

Location: Berkeley, CA, USA

Website: https://www.acrigen.com/

Acrigen Biosciences develops novel high precision gene-editing systems. The company seeks to identify and develop next-generation CRISPR-Cas nucleases using its proprietary AcrTAIN™ bioinformatics discovery software platform. The company also develops its proprietary ErAcr proteins - Engineered Recombinant Anti-CRISPR proteins - that selectively inhibit off-target editing. The company raised seed funding in September 2021.

Acrigen Biosciences

Your Latest CMN News

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Company: Acrigen Biosciences

Search CRISPR Medicine